Asegua Therapeutics LLC, founded in 2018, focuses on enhancing access to critical therapies for patients. The company has introduced authorized generics of two significant antiviral medications: EPCLUSA® (sofosbuvir/velpatasvir) and HARVONI® (ledipasvir/sofosbuvir). These medications are primarily used in the treatment of hepatitis C, and Asegua's commitment to providing these authorized generics aims to improve patient access to effective treatment options. The company emphasizes the importance of patient support and provides resources to assist individuals in navigating their treatment journeys.

In addition to its focus on access, Asegua Therapeutics is affiliated with Gilead Sciences Inc., which underscores its connection to established pharmaceutical expertise and resources. The company’s offerings are designed to ensure that patients receive the necessary information and support regarding their therapies, including comprehensive prescribing information and safety warnings. By prioritizing accessibility and patient education, Asegua Therapeutics aims to make a meaningful impact in the lives of those affected by hepatitis C.

United States

Founded in 2018, Asegua Therapeutics LLChas launched an authorized generic of EPCLUSA®(sofosbuvir/velpatasvir) and an authorized generic of HARVONI®(ledipasvir/sofosbuvir).

Asegua Therapeutics

Company Details